Daewoong Pharmaceutical Co., Ltd's (KRX:069620) 27% Price Boost Is Out Of Tune With Earnings
Jul 24
South Korean (KOSPI) Healthcare Sector Analysis
UpdatedJul 26, 2024
DataAggregated Company Financials
Companies350
- 7D1.3%
- 3M8.9%
- 1Y20.7%
- YTD3.0%
Over the last 7 days, the Healthcare industry has risen 1.3%, driven by gains from Samsung BiologicsLtd of 8.9%. This takes the industry's 12 month performance to a gain of 21%. Earnings are forecast to grow by 36% annually.
Sector Valuation and Performance
Has the South Korean Healthcare Sector valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Fri, 26 Jul 2024 | ₩251.1t | ₩52.3t | ₩750.8b | 16.5x | 334.4x | 4.8x |
| Sun, 23 Jun 2024 | ₩228.8t | ₩53.0t | ₩748.3b | 16.5x | 305.8x | 4.3x |
| Tue, 21 May 2024 | ₩228.6t | ₩52.4t | ₩915.6b | 18.2x | 249.6x | 4.4x |
| Thu, 18 Apr 2024 | ₩223.5t | ₩52.3t | ₩538.5b | 17.3x | 415x | 4.3x |
| Sat, 16 Mar 2024 | ₩237.9t | ₩52.2t | ₩165.1b | 20.8x | 1440.7x | 4.6x |
| Mon, 12 Feb 2024 | ₩220.1t | ₩52.0t | -₩55,498,881,746.00 | 21.3x | -3966.1x | 4.2x |
| Wed, 10 Jan 2024 | ₩231.4t | ₩56.1t | ₩268.5b | 23.8x | 861.8x | 4.1x |
| Fri, 08 Dec 2023 | ₩208.3t | ₩56.1t | ₩284.8b | 22.2x | 731.3x | 3.7x |
| Sun, 05 Nov 2023 | ₩199.5t | ₩56.0t | ₩1.0t | 18x | 194.6x | 3.6x |
| Tue, 03 Oct 2023 | ₩205.1t | ₩56.0t | ₩1.0t | 18.7x | 200.4x | 3.7x |
| Thu, 31 Aug 2023 | ₩215.5t | ₩56.0t | ₩988.6b | 23.3x | 218x | 3.9x |
| Sat, 29 Jul 2023 | ₩208.2t | ₩56.1t | ₩2.1t | 20.6x | 99.6x | 3.7x |
| Mon, 26 Jun 2023 | ₩209.4t | ₩56.3t | ₩2.1t | 20.4x | 99.4x | 3.7x |
| Wed, 24 May 2023 | ₩219.8t | ₩58.1t | ₩3.2t | 20.5x | 69.2x | 3.8x |
| Fri, 21 Apr 2023 | ₩214.7t | ₩58.4t | ₩3.2t | 20.4x | 66.1x | 3.7x |
| Sun, 19 Mar 2023 | ₩205.2t | ₩58.0t | ₩4.3t | 19.4x | 48.2x | 3.5x |
| Tue, 14 Feb 2023 | ₩206.1t | ₩57.8t | ₩4.6t | 18.9x | 44.7x | 3.6x |
| Thu, 12 Jan 2023 | ₩204.9t | ₩58.0t | ₩4.4t | 16.5x | 46.9x | 3.5x |
| Sat, 10 Dec 2022 | ₩209.7t | ₩57.5t | ₩3.9t | 16.6x | 54x | 3.6x |
| Mon, 07 Nov 2022 | ₩206.0t | ₩55.9t | ₩4.0t | 15.2x | 51.3x | 3.7x |
| Wed, 05 Oct 2022 | ₩195.8t | ₩55.7t | ₩4.1t | 15.6x | 47.5x | 3.5x |
| Fri, 02 Sep 2022 | ₩215.8t | ₩56.0t | ₩4.2t | 18.2x | 51.3x | 3.9x |
| Sun, 31 Jul 2022 | ₩226.3t | ₩54.2t | ₩3.9t | 20x | 58.2x | 4.2x |
| Tue, 28 Jun 2022 | ₩210.2t | ₩54.2t | ₩3.9t | 18.4x | 54x | 3.9x |
| Thu, 26 May 2022 | ₩223.0t | ₩52.8t | ₩4.0t | 21.7x | 55.3x | 4.2x |
| Sat, 23 Apr 2022 | ₩222.9t | ₩51.0t | ₩4.0t | 22.5x | 56.1x | 4.4x |
| Mon, 21 Mar 2022 | ₩239.2t | ₩50.5t | ₩4.5t | 22.9x | 53.5x | 4.7x |
| Wed, 16 Feb 2022 | ₩210.5t | ₩49.0t | ₩4.3t | 20.1x | 48.7x | 4.3x |
| Fri, 14 Jan 2022 | ₩251.2t | ₩49.0t | ₩4.3t | 22.8x | 58.1x | 5.1x |
| Sun, 12 Dec 2021 | ₩267.7t | ₩49.0t | ₩4.3t | 25.6x | 62.1x | 5.5x |
| Tue, 09 Nov 2021 | ₩253.7t | ₩48.0t | ₩4.3t | 22x | 59.5x | 5.3x |
| Thu, 07 Oct 2021 | ₩252.1t | ₩48.0t | ₩4.3t | 21.7x | 59.1x | 5.3x |
| Sat, 04 Sep 2021 | ₩321.1t | ₩49.5t | ₩4.3t | 29.6x | 75.1x | 6.5x |
| Mon, 02 Aug 2021 | ₩295.4t | ₩48.8t | ₩4.2t | 29.5x | 69.6x | 6.1x |
Price to Earnings Ratio
69.6x
Current Industry PE
- Investors are optimistic on the South Korean Healthcare industry, and appear confident in long term growth rates.
- The industry is trading at a PE ratio of 334x which is higher than its 3-year average PE of 189x.
- The 3-year average PS ratio of 4.3x is lower than the industry's current PS ratio of 4.8x.
Past Earnings Growth
- The earnings for companies in the Healthcare industry have declined 44% per year over the last three years.
- Meanwhile revenues for these companies have grown 2.3% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.
Industry Trends
Which industries have driven the changes within the South Korean Healthcare sector?
| KR Market | -3.99% | |
| Healthcare | 1.34% | |
| Biotech | 3.92% | |
| Life Sciences | 2.64% | |
| Pharma | -1.52% | |
| Medical Equipment | -2.67% | |
| Healthcare Services | -2.95% | |
| Healthtech | -2.97% | |
Industry PE
- Investors are most optimistic about the Life Sciences industry even though it's trading below its 3-year average PE ratio of 127x.
- Analysts are expecting annual earnings growth of 15.5%, which is higher than its past year's earnings growth of 12.9% per year.
Forecasted Growth
- Analysts are most optimistic on the Healthtech industry, expecting annual earnings growth of 134% over the next 5 years.
- This is better than its past earnings growth rate of 94% per year.
- In contrast, the Life Sciences industry is expected to see its earnings grow by 15% per year over the next few years.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| A207940 Samsung BiologicsLtd | ₩909.00k | 8.9% +₩5.3t | 15.9% | PE72.3x | |
| A068270 Celltrion | ₩200.50k | 6.7% +₩2.6t | 39.4% | PE105x | |
| A145020 Hugel | ₩243.00k | 8.7% +₩214.0b | 137.1% | PE27.3x | |
| A196170 ALTEOGEN | ₩275.50k | 1.5% +₩212.5b | 549.8% | PE573x | |
| A069620 Daewoong Pharmaceutical | ₩130.70k | 10.6% +₩143.8b | 31.6% | PE13.1x |
